PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Atezolizumab

Drugs in development · updated 30 October 2026

Atezolizumab: clinical trials and development status

Other names and codes: Tecentriq, MPDL3280A

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 September 2017

As of 30 October 2026 Atezolizumab is in 294 active clinical trials (recruiting or ongoing, phases I–III) for 106 diseases. The most advanced phase is III.

294Active trials
IIIMost advanced phase
106Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Atezolizumab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 106 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Hepatocellular carcinomaIII44NCT07620574
Non-small-cell lung carcinomaIII34NCT07388524
Lung neoplasmIII29NCT04214262
Lung small cell carcinomaIII27NCT07472517
NeoplasmIII26NCT07620574
Colorectal neoplasmIII19NCT07620574
Bladder neoplasmIII14NCT03775265
Breast neoplasmIII13NCT04873362
MelanomaII–III12NCT05770102
MetastasisIII11NCT06680258
Renal cell carcinomaIII10NCT07620574
Triple-negative breast neoplasmIII9NCT03281954
Prostatic NeoplasmsIII8NCT07620574
Transitional cell carcinomaIII8NCT04637594
Liver neoplasmIII7NCT06680258
Endometrial neoplasmII–III6NCT05770102
Head and neck squamous cell carcinomaII–III6NCT05063552
Malignant mesotheliomaIII5NCT04996017
Ovarian neoplasmII–III5NCT02839707
CarcinomaIII4NCT03755791
Colonic neoplasmIII3NCT02912559
Hematologic neoplasmII–III3NCT05722886
Rectal neoplasmIII3NCT05482516
Brain NeoplasmsIII2NCT05317858
Fallopian tube neoplasmII–III2NCT02839707
Lymphoproliferative disordersII–III2NCT05722886
MesotheliomaIII2NCT04996017
Nasopharyngeal CarcinomaII–III2NCT05063552
Oropharyngeal NeoplasmsII–III2NCT05063552
Colorectal Neoplasms, Hereditary NonpolyposisIII1NCT02912559

Everything on Atezolizumab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch